Cantor Fitzgerald Has Weak Estimate for ZVRA FY2024 Earnings

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Stock analysts at Cantor Fitzgerald cut their FY2024 earnings estimates for shares of Zevra Therapeutics in a report released on Wednesday, November 13th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will post earnings of ($1.97) per share for the year, down from their previous forecast of ($1.61). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.92) per share.

Several other analysts also recently issued reports on ZVRA. Guggenheim started coverage on Zevra Therapeutics in a research note on Monday, October 7th. They issued a “buy” rating and a $20.00 price target for the company. Roth Mkm boosted their target price on shares of Zevra Therapeutics from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Tuesday, September 24th. Canaccord Genuity Group lowered their price target on shares of Zevra Therapeutics from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, November 14th. Maxim Group boosted their price objective on shares of Zevra Therapeutics from $18.00 to $25.00 and gave the company a “buy” rating in a report on Tuesday, September 24th. Finally, William Blair raised Zevra Therapeutics to a “strong-buy” rating in a research report on Friday, August 30th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $21.00.

Zevra Therapeutics Price Performance

NASDAQ:ZVRA opened at $8.97 on Monday. The firm’s fifty day moving average price is $8.06 and its two-hundred day moving average price is $6.54. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88. The company has a market cap of $478.78 million, a P/E ratio of -4.55 and a beta of 1.93. Zevra Therapeutics has a one year low of $4.20 and a one year high of $9.21.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.25). Zevra Therapeutics had a negative return on equity of 159.54% and a negative net margin of 342.63%. The business had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.04 million. During the same period last year, the firm earned ($0.40) EPS.

Institutional Investors Weigh In On Zevra Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Zevra Therapeutics by 3.6% in the first quarter. Vanguard Group Inc. now owns 1,704,006 shares of the company’s stock valued at $9,883,000 after buying an additional 58,866 shares in the last quarter. Price T Rowe Associates Inc. MD bought a new position in shares of Zevra Therapeutics in the 1st quarter valued at $64,000. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Zevra Therapeutics by 102.4% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock valued at $201,000 after acquiring an additional 17,557 shares in the last quarter. Bank of New York Mellon Corp grew its position in Zevra Therapeutics by 10.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 220,499 shares of the company’s stock worth $1,080,000 after acquiring an additional 21,231 shares during the last quarter. Finally, Rhumbline Advisers increased its holdings in Zevra Therapeutics by 17.9% in the 2nd quarter. Rhumbline Advisers now owns 56,874 shares of the company’s stock worth $279,000 after purchasing an additional 8,619 shares in the last quarter. 35.03% of the stock is owned by institutional investors.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.